Sanofi S.A. - Company Snapshot & SWOT Analysis

Publication ID:

NAV0319005

Publication Date:

March 06, 2019

Pages:

Countries:

Global [1]

As per NAVADHI Market Research, the global pharmaceutical industry [2] will we worth USD 1.57 trillion by 2023.

Sanofi S.A. is a Paris based, French multinational pharmaceutical company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions.

Sanofi S.A. 2018 Revenue Performance at a glance

The French drugmaker expected net income to increase by 3-5% in 2019 as it reported slightly higher-than-expected quarterly earnings propelled once again by its rare diseases Genzyme unit.

Sanofi’s fourth-quarter business net income was up 4.3 percent at constant exchange rates to 1.36 billion euros, while revenue rose 3.9 percent to 9 billion. Sales at Genzyme surged 37.4 percent.

Net sales in 2018 were €34,463 million, down 1.7% according to latest report. The decline is mainly due to diabetes and cardiovascular (DCV) business unit performance as unit sales were down by 11.3%.

Spanning over 36 pages and 31 exhibits, “Sanofi S.A. - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.

Scope of the Sanofi S.A.- Company Snapshot & SWOT Analysis Report

This report provides detailed information about Sanofi S.A. including value chain analysis, financial performance, business strategy and SWOT analysis.
The report identifies the growth drivers and inhibitors for global pharmaceutical market.
This report provides information about current and future trends for global pharmaceutical market.

1. Executive Summary

Scope of the Sanofi S.A.- Company Snapshot & SWOT Analysis Report

Research Methodology

2. Growth Drivers and Inhibitors for Global Pharmaceuticals Market

3. Company Profile

3.1 Sanofi S.A.

3.1.1. Company Profile

3.1.2 Sanofi S.A. in Global Pharmaceuticals Manufacturing Value Chain

3.1.3 Sanofi S.A.: Financial Performance

3.1.3.1 Sanofi S.A.: Geography wise Performance

3.1.4 Sanofi S.A.: Business Strategy

3.1.4.1 Sanofi S.A. Revenue by Global Business Units (GBU’s)

3.1.4.2 Sanofi S.A. Revenue by Global Franchise

3.1.5 SWOT Analysis of Sanofi S.A.

Strengths

Weaknesses

Opportunities

Threats

3.1.6 Sanofi’s TOP 10 Blockbusters Drugs Revenue in FY 2018 (in Euro millions)

4. Current and Future Trends in Pharmaceutical Market

List of Exhibits

Notes

List of Exhibits

Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market

Exhibit 3.1 Key Information of Sanofi S.A.

Exhibit 3.2 Contact Information of Sanofi S.A.

Exhibit 3.3 Sanofi S.A. in Global Pharmaceuticals Manufacturing Value Chain

Exhibit 3.4 Sanofi S.A. Revenue FY2014-2019 (in Euro billion)

Exhibit 3.5 Year-wise Sanofi S.A. Growth 2014-19 (in %)

Exhibit 3.6 Geography-wise Sanofi S.A. Revenue Share FY 2018 (in %)

Exhibit 3.7 Geography-wise Sanofi S.A. Revenue FY 2017-2018 (in Euro million)

Exhibit 3.8 Global Business Units (GBU’s)-wise Sanofi S.A. Revenue FY 2018 (in %)

Exhibit 3.9 Global Business Units (GBU’s)-wise Sanofi S.A. Revenue FY 2017-2018 (in Euro million)

Exhibit 3.10 Global Franchise-wise Sanofi S.A. Revenue FY 2018 (in %)

Exhibit 3.11 Global Franchise-wise Sanofi S.A. Revenue FY 2017-2018 (in Euro million)

Exhibit 3.12 Sanofi S.A. Specialty Care Franchise Revenue FY 2018 (in %)

Exhibit 3.13 Sanofi S.A. Specialty Care Franchise Revenue FY 2015-2018 (in Euro million)

Exhibit 3.14 Sanofi S.A. Rare Diseases Franchise Revenue FY 2017-2018 (in Euro million)

Exhibit 3.15 Sanofi S.A. Multiple Sclerosis Franchise Revenue FY 2017-2018 (in Euro million)

Exhibit 3.16 Sanofi S.A. Oncology Franchise Revenue FY 2017-2018 (in Euro million)

Exhibit 3.17 Sanofi S.A. Immunology Franchise Revenue FY 2017-2018 (in Euro million)

Exhibit 3.18 Sanofi S.A. Rare Blood Disorder Franchise Revenue FY 2017-2018 (in Euro million)

Exhibit 3.19 Sanofi S.A. Diabetes and Cardiovascular (DCV) Franchise Revenue FY 2015-2018 (in Euro million)

Exhibit 3.20 Sanofi S.A. Diabetes Franchise Revenue By Brands FY 2017-2018 (in Euro million)

Exhibit 3.21 Sanofi S.A. Cardiovascular Franchise Revenue By Brands FY 2017-2018 (in Euro million)

Exhibit 3.22 Sanofi S.A. Established Rx Products Franchise Revenue FY 2015-2018 (in Euro million)

Exhibit 3.23 Sanofi S.A. Established Rx Products Franchise Revenue By Brands FY 2017-2018 (in Euro million)

Exhibit 3.24 Sanofi S.A. Consumer Healthcare (CHC) Franchise Revenue FY 2015-2018 (in Euro million)

Exhibit 3.25 Sanofi S.A. Consumer Healthcare (CHC) Franchise Revenue By Brands FY 2017-2018 (in Euro million)

Exhibit 3.26 Sanofi S.A. Generic Franchise Revenue FY 2015-2018 (in Euro million)

Exhibit 3.27 Sanofi S.A. Vaccines Franchise Revenue FY 2015-2018 (in Euro million)

Exhibit 3.28 Sanofi S.A. Vaccines Franchise Revenue By Brands FY 2017-2018 (in Euro million)

Exhibit 3.29 SWOT Analysis of Sanofi S.A.

Exhibit 3.30 Top 10 Blockbuster Drug Revenue of Sanofi (in Euro millions)

Sanofi S.A.

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Enterprise License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.